{"protocolSection": {"identificationModule": {"nctId": "NCT02245672", "orgStudyIdInfo": {"id": "MGR001-3001"}, "organization": {"fullName": "Viatris Inc.", "class": "INDUSTRY"}, "briefTitle": "MGR001 / Advair Diskus Local Equivalence Study in Asthma", "officialTitle": "A Randomized, Double-blind, Double Dummy, Parallel Group Study to Determine the Local Equivalence of Multiple Doses of MGR001 to Advair Diskus Administered Via Oral Inhalation in Adult Asthma Patients"}, "statusModule": {"statusVerifiedDate": "2022-02", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2014-10"}, "primaryCompletionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "completionDateStruct": {"date": "2015-07", "type": "ACTUAL"}, "studyFirstSubmitDate": "2014-09-15", "studyFirstSubmitQcDate": "2014-09-17", "studyFirstPostDateStruct": {"date": "2014-09-19", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2020-11-13", "resultsFirstSubmitQcDate": "2020-12-17", "resultsFirstPostDateStruct": {"date": "2021-01-12", "type": "ACTUAL"}, "dispFirstSubmitDate": "2016-05-25", "dispFirstSubmitQcDate": "2016-05-25", "dispFirstPostDateStruct": {"date": "2016-06-06", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2022-02-22", "lastUpdatePostDateStruct": {"date": "2022-02-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Mylan Pharma UK Ltd.", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to determine whether MGR001 is equivalent to Advair Diskus when administered by inhalation in adult asthma patients"}, "conditionsModule": {"conditions": ["Asthma"], "keywords": ["Asthma", "fluticasone", "salmeterol", "CRC749", "Diskus", "Advair", "FEV1", "MGR001"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 1128, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MGR001", "type": "EXPERIMENTAL", "description": "MGR001 administered two times per day by inhalation throughout the study", "interventionNames": ["Drug: MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)"]}, {"label": "Advair Diskus", "type": "ACTIVE_COMPARATOR", "description": "Advair Diskus administered two times per day by inhalation throughout the study", "interventionNames": ["Drug: Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study", "interventionNames": ["Drug: Placebo"]}], "interventions": [{"type": "DRUG", "name": "MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)", "description": "Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device", "armGroupLabels": ["MGR001"]}, {"type": "DRUG", "name": "Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)", "description": "Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device", "armGroupLabels": ["Advair Diskus"]}, {"type": "DRUG", "name": "Placebo", "description": "Placebo administered via the CRC749 and Diskus devices", "armGroupLabels": ["Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity)", "description": "The FEV1 AUEC(0-12) on Day 1 was calculated from FEV1 measurements collected 30 minutes prior to morning dose, 0 minutes prior to morning dose, and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours following completion of dosing on Day 1 (Visit 3). The baseline for the FEV1 AUEC(0-12) endpoint was the mean of the 2 predose FEV1 measures. To confirm assay sensitivity, both active treatments (MGR001 and Advair Diskus) had to be significantly superior to placebo", "timeFrame": "0-12 hours after dosing on Day 1"}, {"measure": "Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Bioequivalence)", "description": "The FEV1 AUEC(0-12) on Day 1 was calculated from FEV1 measurements collected 30 minutes prior to morning dose, 0 minutes prior to morning dose, and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours following completion of dosing on Day 1 (Visit 3). The baseline for the FEV1 AUEC(0-12) endpoint was the mean of the 2 predose FEV1 measures", "timeFrame": "0-12 hours after dosing on Day 1"}, {"measure": "FEV1 Trough Value (Assay Sensitivity)", "description": "Change from baseline in trough (pre-dose) FEV1 at Day 29 was based on 2 pre-dose FEV1 assessments performed 30 minutes apart on Day 29. Baseline was calculated by taking the mean of \\[prebronchodilator FEV1 measured at a run-in visit and the mean of 2 predose FEV1 measures taken at Day 1\\]. To confirm assay sensitivity, both active treatments (MGR001 and Advair Diskus) had to be significantly superior to placebo.", "timeFrame": "Day 1 and Day 29"}, {"measure": "FEV1 Trough Value (Bioequivalence)", "description": "Change from baseline in trough (pre-dose) FEV1 at Day 29 was based on 2 pre-dose FEV1 assessments performed 30 minutes apart on Day 29. Baseline was calculated by taking the mean of \\[prebronchodilator FEV1 measured at a run-in visit and the mean of 2 predose FEV1 measures taken at Day 1\\]", "timeFrame": "Day 1 and Day 29"}]}, "eligibilityModule": {"eligibilityCriteria": "Key inclusion criteria include:\n\n* Male or female subjects aged \u226518 years. Females may be of either childbearing or non-childbearing potential\n* Physician diagnosed history of asthma for at least 12 weeks prior to screening\n* pre-bronchodilator FEV1 60-85% at screening and other specified visits\n* Post-bronchodilator reversibility \\>/=12%\n* Non-smokers and prior smokers with no history of smoking within the past 12 months prior to screening and a total smoking history of \u226410 pack-years\n* Subjects able to discontinue asthma medications for the duration of the study and be maintained using albuterol as required\n* Body mass index between 18-40 kg/m2 inclusive\n\nKey exclusion criteria include:\n\n* Presence or recent history of any other active, severe, progressive, and/or uncontrolled clinical disease, eg, poorly controlled Type 1 or 2 diabetes, seizure disorder or epilepsy, cerebrovascular accident, significant cardiac conduction abnormalities\n* Respiratory conditions other than asthma and allergic rhinitis, including but not limited to: severe nasal polyposis or chronic rhinosinusitis, chronic obstructive pulmonary disease, bronchiectasis, Churg-Strauss Disease, lung resection, pulmonary fibrosis (primary or secondary), pulmonary hypertension, cystic fibrosis, sarcoidosis\n* History of life-threatening asthma, defined as a history of asthma episode(s) requiring intubation, and/or associated with hypercapnia; respiratory arrest or hypoxic seizures, asthma related syncopal episode(s)\n* In patient hospitalization (not including ER visits) for an asthma exacerbation within the past year or during the run in period\n* An asthma exacerbation requiring change in asthma therapy or oral/IV corticosteroids in the 3 months prior to screening\n* History of seasonally unstable asthma where the season will coincide with the subject's participation in the study\n* Use of prescription or non-prescription drugs, including beta blockers, tricyclic antidepressants, oral decongestants, benzodiazepines, digitalis, phenothiazines, monoamine oxidase inhibitors, etc\n* Suspected hypersensitivity to the study drugs (including lactose) or severe milk protein allergy\n* Clinically significant abnormalities in the screening ECG\n* Evidence of alcohol or drug abuse or dependency within 6 months prior to screening", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Dik WH Ng, PhD", "affiliation": "Mylan Pharma UK Ltd.", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Mylan Investigative Site #1", "city": "Birmingham", "state": "Alabama", "zip": "35209", "country": "United States", "geoPoint": {"lat": 33.52066, "lon": -86.80249}}, {"facility": "Mylan Investigative Site #2", "city": "Little Rock", "state": "Arkansas", "zip": "72205", "country": "United States", "geoPoint": {"lat": 34.74648, "lon": -92.28959}}, {"facility": "Mylan Investigative Site #3", "city": "Anaheim", "state": "California", "zip": "92801", "country": "United States", "geoPoint": {"lat": 33.83529, "lon": -117.9145}}, {"facility": "Mylan Investigative Site #4", "city": "Bakersfield", "state": "California", "zip": "93301", "country": "United States", "geoPoint": {"lat": 35.37329, "lon": -119.01871}}, {"facility": "Mylan Investigative Site #5", "city": "Burbank", "state": "California", "zip": "91505", "country": "United States", "geoPoint": {"lat": 34.18084, "lon": -118.30897}}, {"facility": "Mylan Investigative Site #6", "city": "Costa Mesa", "state": "California", "zip": "92626", "country": "United States", "geoPoint": {"lat": 33.64113, "lon": -117.91867}}, {"facility": "Mylan Investigative Site #7", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Mylan Investigative Site #8", "city": "Fresno", "state": "California", "zip": "93720", "country": "United States", "geoPoint": {"lat": 36.74773, "lon": -119.77237}}, {"facility": "Mylan Investigative Site #9", "city": "Fullerton", "state": "California", "zip": "92835", "country": "United States", "geoPoint": {"lat": 33.87029, "lon": -117.92534}}, {"facility": "Mylan Investigative Site #10", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Mylan Investigative Site #11", "city": "Huntington Beach", "state": "California", "zip": "92647", "country": "United States", "geoPoint": {"lat": 33.6603, "lon": -117.99923}}, {"facility": "Mylan Investigative Site #12", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Mylan Investigative Site #13", "city": "Los Angeles", "state": "California", "zip": "90025", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Mylan Investigative Site #14", "city": "Los Angeles", "state": "California", "zip": "90048", "country": "United States", "geoPoint": {"lat": 34.05223, "lon": -118.24368}}, {"facility": "Mylan Investigative Site #15", "city": "Mission Viejo", "state": "California", "zip": "92691", "country": "United States", "geoPoint": {"lat": 33.60002, "lon": -117.672}}, {"facility": "Mylan Investigative Site #16", "city": "Napa", "state": "California", "zip": "94558", "country": "United States", "geoPoint": {"lat": 38.29714, "lon": -122.28553}}, {"facility": "Mylan Investigative Site #17", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Mylan Investigative Site #18", "city": "Riverside", "state": "California", "zip": "92506", "country": "United States", "geoPoint": {"lat": 33.95335, "lon": -117.39616}}, {"facility": "Mylan Investigational Site #27", "city": "Rolling Hills Estates", "state": "California", "zip": "90274", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -118.35813}}, {"facility": "Mylan Investigative Site #19", "city": "Sacramento", "state": "California", "zip": "95842", "country": "United States", "geoPoint": {"lat": 38.58157, "lon": -121.4944}}, {"facility": "Mylan Investigative Site #20", "city": "San Diego", "state": "California", "zip": "92123", "country": "United States", "geoPoint": {"lat": 32.71533, "lon": -117.15726}}, {"facility": "Mylan Investigative Site #21", "city": "San Jose", "state": "California", "zip": "95117", "country": "United States", "geoPoint": {"lat": 37.33939, "lon": -121.89496}}, {"facility": "Mylan Investigative Site #101", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Mylan Investigative Site #22", "city": "Centennial", "state": "Colorado", "zip": "80112", "country": "United States", "geoPoint": {"lat": 39.57916, "lon": -104.87692}}, {"facility": "Mylan Investigative Site #23", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Mylan Investigative Site #24", "city": "Colorado Springs", "state": "Colorado", "zip": "80907", "country": "United States", "geoPoint": {"lat": 38.83388, "lon": -104.82136}}, {"facility": "Mylan Investigative Site #25", "city": "Denver", "state": "Colorado", "zip": "80230", "country": "United States", "geoPoint": {"lat": 39.73915, "lon": -104.9847}}, {"facility": "Mylan Investigative Site #26", "city": "Wheat Ridge", "state": "Colorado", "zip": "80033", "country": "United States", "geoPoint": {"lat": 39.7661, "lon": -105.07721}}, {"facility": "Mylan Investigative Site #28", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Mylan Investigative Site #29", "city": "Gainesville", "state": "Florida", "zip": "32607", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Mylan Investigative Site #30", "city": "Hialeah", "state": "Florida", "zip": "33012", "country": "United States", "geoPoint": {"lat": 25.8576, "lon": -80.27811}}, {"facility": "Mylan Investigative Site #31", "city": "Largo", "state": "Florida", "zip": "33770", "country": "United States", "geoPoint": {"lat": 27.90979, "lon": -82.78842}}, {"facility": "Mylan Investigative Site #32", "city": "Miami", "state": "Florida", "zip": "33015", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Mylan Investigative Site #34", "city": "Miami", "state": "Florida", "zip": "33133", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Mylan Investigative Site #33", "city": "Miami", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Mylan Investigative Site #35", "city": "Miami", "state": "Florida", "zip": "33155", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Mylan Investigative Site #36", "city": "New Port Richey", "state": "Florida", "zip": "34653", "country": "United States", "geoPoint": {"lat": 28.24418, "lon": -82.71927}}, {"facility": "Mylan Investigative Site #37", "city": "Tallahassee", "state": "Florida", "zip": "32308", "country": "United States", "geoPoint": {"lat": 30.43826, "lon": -84.28073}}, {"facility": "Mylan Investigative Site #38", "city": "Lawrenceville", "state": "Georgia", "zip": "30046", "country": "United States", "geoPoint": {"lat": 33.95621, "lon": -83.98796}}, {"facility": "Mylan Investigative Site #39", "city": "River Forest", "state": "Illinois", "zip": "60305", "country": "United States", "geoPoint": {"lat": 41.89781, "lon": -87.81395}}, {"facility": "Mylan Investigative Site #40", "city": "Shiloh", "state": "Illinois", "zip": "62269", "country": "United States", "geoPoint": {"lat": 38.56144, "lon": -89.89732}}, {"facility": "Mylan Investigative Site #41", "city": "Lenexa", "state": "Kansas", "zip": "66219", "country": "United States", "geoPoint": {"lat": 38.95362, "lon": -94.73357}}, {"facility": "Mylan Investigative Site #42", "city": "Bangor", "state": "Maine", "zip": "04401", "country": "United States", "geoPoint": {"lat": 44.80118, "lon": -68.77781}}, {"facility": "Mylan Investigative Site #43", "city": "Baltimore", "state": "Maryland", "zip": "21236", "country": "United States", "geoPoint": {"lat": 39.29038, "lon": -76.61219}}, {"facility": "Mylan Investigative Site #44", "city": "Bethesda", "state": "Maryland", "zip": "20814", "country": "United States", "geoPoint": {"lat": 38.98067, "lon": -77.10026}}, {"facility": "Mylan Investigative Site #45", "city": "Wheaton", "state": "Maryland", "zip": "20902", "country": "United States", "geoPoint": {"lat": 39.03983, "lon": -77.05526}}, {"facility": "Mylan Investigative Site #46", "city": "White Marsh", "state": "Maryland", "zip": "21162", "country": "United States", "geoPoint": {"lat": 39.38372, "lon": -76.43218}}, {"facility": "Mylan Investigative Site #47", "city": "Fall River", "state": "Massachusetts", "zip": "02720", "country": "United States", "geoPoint": {"lat": 41.70149, "lon": -71.15505}}, {"facility": "Mylan Investigative Site #48", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Mylan Investigative Site #49", "city": "North Dartmouth", "state": "Massachusetts", "zip": "02747", "country": "United States", "geoPoint": {"lat": 41.63899, "lon": -70.97032}}, {"facility": "Mylan Investigative Site #50", "city": "Minneapolis", "state": "Minnesota", "zip": "55402", "country": "United States", "geoPoint": {"lat": 44.97997, "lon": -93.26384}}, {"facility": "Mylan Investigative Site #51", "city": "Columbia", "state": "Missouri", "zip": "65203", "country": "United States", "geoPoint": {"lat": 38.95171, "lon": -92.33407}}, {"facility": "Mylan Investigative Site #52", "city": "Rolla", "state": "Missouri", "zip": "65401", "country": "United States", "geoPoint": {"lat": 37.95143, "lon": -91.77127}}, {"facility": "Mylan Investigative Site #53", "city": "Saint Louis", "state": "Missouri", "zip": "63141", "country": "United States", "geoPoint": {"lat": 38.62727, "lon": -90.19789}}, {"facility": "Mylan Investigative Site #54", "city": "Warrensburg", "state": "Missouri", "zip": "64093", "country": "United States", "geoPoint": {"lat": 38.76279, "lon": -93.73605}}, {"facility": "Mylan Investigative Site #55", "city": "Bozeman", "state": "Montana", "zip": "59718", "country": "United States", "geoPoint": {"lat": 45.67965, "lon": -111.03856}}, {"facility": "Mylan Investigative Site #56", "city": "Missoula", "state": "Montana", "zip": "59808", "country": "United States", "geoPoint": {"lat": 46.87215, "lon": -113.994}}, {"facility": "Mylan Investigative Site #57", "city": "Bellevue", "state": "Nebraska", "zip": "68123-4303", "country": "United States", "geoPoint": {"lat": 41.13667, "lon": -95.89084}}, {"facility": "Mylan Investigative Site #58", "city": "Brick", "state": "New Jersey", "zip": "08724", "country": "United States", "geoPoint": {"lat": 40.05928, "lon": -74.13708}}, {"facility": "Mylan Investigative Site #59", "city": "Ocean City", "state": "New Jersey", "zip": "07712", "country": "United States", "geoPoint": {"lat": 39.27762, "lon": -74.5746}}, {"facility": "Mylan Investigative Site #60", "city": "Skillman", "state": "New Jersey", "zip": "08558", "country": "United States", "geoPoint": {"lat": 40.42011, "lon": -74.7146}}, {"facility": "Mylan Investigative Site #61", "city": "New York", "state": "New York", "zip": "11570", "country": "United States", "geoPoint": {"lat": 40.71427, "lon": -74.00597}}, {"facility": "Mylan Investigative Site #62", "city": "Asheville", "state": "North Carolina", "zip": "28801", "country": "United States", "geoPoint": {"lat": 35.60095, "lon": -82.55402}}, {"facility": "Mylan Investigative Site #63", "city": "Charlotte", "state": "North Carolina", "zip": "28207", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Mylan Investigative Site #64", "city": "Raleigh", "state": "North Carolina", "zip": "27607", "country": "United States", "geoPoint": {"lat": 35.7721, "lon": -78.63861}}, {"facility": "Mylan Investigative Site #65", "city": "Canton", "state": "Ohio", "zip": "44718", "country": "United States", "geoPoint": {"lat": 40.79895, "lon": -81.37845}}, {"facility": "Mylan Investigative Site #66", "city": "Cincinnati", "state": "Ohio", "zip": "45231", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Mylan Investigative Site #67", "city": "Cincinnati", "state": "Ohio", "zip": "45242", "country": "United States", "geoPoint": {"lat": 39.12713, "lon": -84.51435}}, {"facility": "Mylan Investigative Site #68", "city": "Sylvania", "state": "Ohio", "zip": "43560", "country": "United States", "geoPoint": {"lat": 41.71894, "lon": -83.71299}}, {"facility": "Mylan Investigative Site #69", "city": "Toledo", "state": "Ohio", "zip": "43617", "country": "United States", "geoPoint": {"lat": 41.66394, "lon": -83.55521}}, {"facility": "Mylan Investigative Site #70", "city": "Oklahoma City", "state": "Oklahoma", "zip": "73112", "country": "United States", "geoPoint": {"lat": 35.46756, "lon": -97.51643}}, {"facility": "Mylan Investigative Site #71", "city": "Tulsa", "state": "Oklahoma", "zip": "74136-8303", "country": "United States", "geoPoint": {"lat": 36.15398, "lon": -95.99277}}, {"facility": "Mylan Investigative Site #72", "city": "Eugene", "state": "Oregon", "zip": "97401", "country": "United States", "geoPoint": {"lat": 44.05207, "lon": -123.08675}}, {"facility": "Mylan Investigative Site #73", "city": "Lake Oswego", "state": "Oregon", "zip": "97035", "country": "United States", "geoPoint": {"lat": 45.42067, "lon": -122.67065}}, {"facility": "Mylan Investigative Site #74", "city": "Medford", "state": "Oregon", "zip": "97504", "country": "United States", "geoPoint": {"lat": 42.32652, "lon": -122.87559}}, {"facility": "Mylan Investigative Site #75", "city": "Portland", "state": "Oregon", "zip": "97202", "country": "United States", "geoPoint": {"lat": 45.52345, "lon": -122.67621}}, {"facility": "Mylan Investigative Site #76", "city": "Jenkintown", "state": "Pennsylvania", "zip": "19046", "country": "United States", "geoPoint": {"lat": 40.09594, "lon": -75.12517}}, {"facility": "Mylan Investigative Site #77", "city": "Pittsburgh", "state": "Pennsylvania", "zip": "15243", "country": "United States", "geoPoint": {"lat": 40.44062, "lon": -79.99589}}, {"facility": "Mylan Investigative Site #78", "city": "Smithfield", "state": "Pennsylvania", "zip": "15478", "country": "United States", "geoPoint": {"lat": 39.80313, "lon": -79.80783}}, {"facility": "Mylan Investigative Site #79", "city": "Providence", "state": "Rhode Island", "zip": "02906", "country": "United States", "geoPoint": {"lat": 41.82399, "lon": -71.41283}}, {"facility": "Mylan Investigative Site #80", "city": "Warwick", "state": "Rhode Island", "zip": "02886", "country": "United States", "geoPoint": {"lat": 41.7001, "lon": -71.41617}}, {"facility": "Mylan Investigative Site #81", "city": "North Charleston", "state": "South Carolina", "zip": "29420", "country": "United States", "geoPoint": {"lat": 32.85462, "lon": -79.97481}}, {"facility": "Mylan Investigative Site #82", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Mylan Investigative Site #83", "city": "Spartanburg", "state": "South Carolina", "zip": "29303", "country": "United States", "geoPoint": {"lat": 34.94957, "lon": -81.93205}}, {"facility": "Mylan Investigative Site #84", "city": "Boerne", "state": "Texas", "zip": "78006", "country": "United States", "geoPoint": {"lat": 29.79466, "lon": -98.73197}}, {"facility": "Mylan Investigative Site #85", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Mylan Investigative Site #86", "city": "Dallas", "state": "Texas", "zip": "75231", "country": "United States", "geoPoint": {"lat": 32.78306, "lon": -96.80667}}, {"facility": "Mylan Investigative Site #87", "city": "Dickinson", "state": "Texas", "zip": "77539", "country": "United States", "geoPoint": {"lat": 29.46079, "lon": -95.05132}}, {"facility": "Mylan Investigative Site #88", "city": "El Paso", "state": "Texas", "zip": "79903", "country": "United States", "geoPoint": {"lat": 31.75872, "lon": -106.48693}}, {"facility": "Mylan Investigative Site #89", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Mylan Investigative Site #90", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Mylan Investigative Site #91", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Mylan Investigative Site #92", "city": "Waco", "state": "Texas", "zip": "76712", "country": "United States", "geoPoint": {"lat": 31.54933, "lon": -97.14667}}, {"facility": "Mylan Investigative Site #93", "city": "Provo", "state": "Utah", "zip": "84604", "country": "United States", "geoPoint": {"lat": 40.23384, "lon": -111.65853}}, {"facility": "Mylan Investigative Site #94", "city": "South Burlington", "state": "Vermont", "zip": "05403", "country": "United States", "geoPoint": {"lat": 44.46699, "lon": -73.17096}}, {"facility": "Mylan Investigative Site #95", "city": "Henrico", "state": "Virginia", "zip": "23233", "country": "United States", "geoPoint": {"lat": 36.59264, "lon": -78.61611}}, {"facility": "Mylan Investigative Site #96", "city": "Seattle", "state": "Washington", "zip": "98115", "country": "United States", "geoPoint": {"lat": 47.60621, "lon": -122.33207}}, {"facility": "Mylan Investigative Site #97", "city": "Spokane", "state": "Washington", "zip": "99204", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Mylan Investigative Site #98", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Mylan Investigative Site #99", "city": "Tacoma", "state": "Washington", "zip": "98405", "country": "United States", "geoPoint": {"lat": 47.25288, "lon": -122.44429}}, {"facility": "Mylan Investigative Site #100", "city": "Greenfield", "state": "Wisconsin", "zip": "53228", "country": "United States", "geoPoint": {"lat": 42.9614, "lon": -88.01259}}]}, "referencesModule": {"references": [{"pmid": "31634023", "type": "RESULT", "citation": "Ng D, Kerwin EM, White MV, Miller SD, Haughie S, Ward JK, Allan R. Clinical Bioequivalence of Wixela Inhub and Advair Diskus in Adults With Asthma. J Aerosol Med Pulm Drug Deliv. 2020 Apr;33(2):99-107. doi: 10.1089/jamp.2019.1547. Epub 2019 Oct 31."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device"}, {"id": "FG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device"}, {"id": "FG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "512"}, {"groupId": "FG001", "numSubjects": "513"}, {"groupId": "FG002", "numSubjects": "103"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "499"}, {"groupId": "FG001", "numSubjects": "500"}, {"groupId": "FG002", "numSubjects": "98"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "13"}, {"groupId": "FG002", "numSubjects": "5"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "4"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "5"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Randomized in error (not treated)", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "The baseline analysis population included all subjects who were randomized and received at least one dose of double-blind study medication. One subject was randomized in error to the Advair Diskus group but was not treated and so not included in the baseline analysis population", "groups": [{"id": "BG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device"}, {"id": "BG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device"}, {"id": "BG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "512"}, {"groupId": "BG001", "value": "512"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "1127"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.6", "spread": "14.08"}, {"groupId": "BG001", "value": "42.5", "spread": "14.21"}, {"groupId": "BG002", "value": "43.5", "spread": "13.85"}, {"groupId": "BG003", "value": "42.6", "spread": "14.11"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "306"}, {"groupId": "BG001", "value": "309"}, {"groupId": "BG002", "value": "64"}, {"groupId": "BG003", "value": "679"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "206"}, {"groupId": "BG001", "value": "203"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "448"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "102"}, {"groupId": "BG001", "value": "92"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "218"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "410"}, {"groupId": "BG001", "value": "420"}, {"groupId": "BG002", "value": "79"}, {"groupId": "BG003", "value": "909"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "11"}, {"groupId": "BG001", "value": "11"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "23"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "2"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "92"}, {"groupId": "BG001", "value": "98"}, {"groupId": "BG002", "value": "22"}, {"groupId": "BG003", "value": "212"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "378"}, {"groupId": "BG001", "value": "372"}, {"groupId": "BG002", "value": "73"}, {"groupId": "BG003", "value": "823"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "30"}, {"groupId": "BG001", "value": "31"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "67"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "512"}, {"groupId": "BG001", "value": "512"}, {"groupId": "BG002", "value": "103"}, {"groupId": "BG003", "value": "1127"}]}]}]}, {"title": "Body Mass Index (BMI)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m^2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "29.38", "spread": "6.026"}, {"groupId": "BG001", "value": "29.12", "spread": "5.886"}, {"groupId": "BG002", "value": "29.37", "spread": "5.890"}, {"groupId": "BG003", "value": "29.26", "spread": "5.947"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Assay Sensitivity)", "description": "The FEV1 AUEC(0-12) on Day 1 was calculated from FEV1 measurements collected 30 minutes prior to morning dose, 0 minutes prior to morning dose, and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours following completion of dosing on Day 1 (Visit 3). The baseline for the FEV1 AUEC(0-12) endpoint was the mean of the 2 predose FEV1 measures. To confirm assay sensitivity, both active treatments (MGR001 and Advair Diskus) had to be significantly superior to placebo", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L*hr", "timeFrame": "0-12 hours after dosing on Day 1", "groups": [{"id": "OG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device"}, {"id": "OG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device"}, {"id": "OG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "508"}, {"groupId": "OG001", "value": "510"}, {"groupId": "OG002", "value": "102"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.9534", "spread": "0.1609"}, {"groupId": "OG001", "value": "3.4964", "spread": "0.1595"}, {"groupId": "OG002", "value": "0.8191", "spread": "0.3477"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "MGR001 (Test) vs Placebo", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "In order for the bioequivalence results to be valid, assay sensitivity had to be established. For assay sensitivity, the following comparisons were performed using the Full Analysis Set for each co-primary endpoint: MGR001 versus placebo, and Advair Diskus versus placebo. Assay sensitivity was demonstrated if the p-values for active treatment versus placebo were less than 0.05", "pValue": "<0.0001", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Advair Diskus (Reference) vs Placebo", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "In order for the bioequivalence results to be valid, assay sensitivity had to be established.For assay sensitivity, the following comparisons were performed using the Full Analysis Set for each co-primary endpoint: MGR001 versus placebo, and Advair Diskus versus placebo. Assay sensitivity was demonstrated if the p-values for active treatment versus placebo were less than 0.05", "pValue": "<0.0001", "statisticalMethod": "ANCOVA"}]}, {"type": "PRIMARY", "title": "Forced Exhaled Volume in 1 Sec (FEV1) Area Under the Effect Curve on Day 1 (Bioequivalence)", "description": "The FEV1 AUEC(0-12) on Day 1 was calculated from FEV1 measurements collected 30 minutes prior to morning dose, 0 minutes prior to morning dose, and at 0.5, 1, 2, 3, 4, 6, 8, 10, and 12 hours following completion of dosing on Day 1 (Visit 3). The baseline for the FEV1 AUEC(0-12) endpoint was the mean of the 2 predose FEV1 measures", "populationDescription": "Per Protocol Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L*hr", "timeFrame": "0-12 hours after dosing on Day 1", "groups": [{"id": "OG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device"}, {"id": "OG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device"}, {"id": "OG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "497"}, {"groupId": "OG001", "value": "494"}, {"groupId": "OG002", "value": "94"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.9734", "spread": "0.1704"}, {"groupId": "OG001", "value": "3.5411", "spread": "0.1593"}, {"groupId": "OG002", "value": "0.8400", "spread": "0.2983"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Equivalence of MGR001 and Advair Diskus is established if the ratio of the LS means and 90% confidence interval are wholly contained within the interval 0.80-1.25 (i.e., 80%-125%).", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "A linear analysis of covariance (ANCOVA) model was fitted for the endpoint and least-squares (LS) means were derived for each treatment. To assess equivalence, LS means (one for Test and one for Reference) from the ANCOVA models were used to generate Test/Reference ratios and 90% CIs were calculated by using Fieller's theorem. To demonstrate equivalence, the 90% CIs were each required to be wholly contained within the interval 0.80-1.25 (i.e., 80%-125%).", "paramType": "Ratio (MGR001/Advair Diskus)", "paramValue": "1.120", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.016", "ciUpperLimit": "1.237", "estimateComment": "Bioequivalence was established between active treatments (MGR001 and Advair Diskus) for the FEV1 AUEC0-12 clinical endpoint"}]}, {"type": "PRIMARY", "title": "FEV1 Trough Value (Assay Sensitivity)", "description": "Change from baseline in trough (pre-dose) FEV1 at Day 29 was based on 2 pre-dose FEV1 assessments performed 30 minutes apart on Day 29. Baseline was calculated by taking the mean of \\[prebronchodilator FEV1 measured at a run-in visit and the mean of 2 predose FEV1 measures taken at Day 1\\]. To confirm assay sensitivity, both active treatments (MGR001 and Advair Diskus) had to be significantly superior to placebo.", "populationDescription": "Full Analysis Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L", "timeFrame": "Day 1 and Day 29", "groups": [{"id": "OG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device"}, {"id": "OG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device"}, {"id": "OG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "504"}, {"groupId": "OG001", "value": "505"}, {"groupId": "OG002", "value": "100"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2927", "spread": "0.0162"}, {"groupId": "OG001", "value": "0.2720", "spread": "0.0161"}, {"groupId": "OG002", "value": "0.0575", "spread": "0.0353"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "MGR001 (Test) vs Placebo", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "In order for the bioequivalence results to be valid, assay sensitivity had to be established. For assay sensitivity, the following comparisons were performed using the Full Analysis Set for each co-primary endpoint: MGR001 versus placebo, and Advair Diskus versus placebo. Assay sensitivity was demonstrated if the p-values for active treatment versus placebo were less than 0.05", "pValue": "<0.0001", "statisticalMethod": "ANCOVA"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Advair Diskus (Reference) vs Placebo", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "In order for the bioequivalence results to be valid, assay sensitivity had to be established. For assay sensitivity, the following comparisons were performed using the Full Analysis Set for each co-primary endpoint: MGR001 versus placebo, and Advair Diskus versus placebo. Assay sensitivity was demonstrated if the p-values for active treatment versus placebo were less than 0.05", "pValue": "<0.0001", "statisticalMethod": "ANCOVA"}]}, {"type": "PRIMARY", "title": "FEV1 Trough Value (Bioequivalence)", "description": "Change from baseline in trough (pre-dose) FEV1 at Day 29 was based on 2 pre-dose FEV1 assessments performed 30 minutes apart on Day 29. Baseline was calculated by taking the mean of \\[prebronchodilator FEV1 measured at a run-in visit and the mean of 2 predose FEV1 measures taken at Day 1\\]", "populationDescription": "Per Protocol Set", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "L", "timeFrame": "Day 1 and Day 29", "groups": [{"id": "OG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device"}, {"id": "OG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device"}, {"id": "OG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "498"}, {"groupId": "OG001", "value": "497"}, {"groupId": "OG002", "value": "99"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.2911", "spread": "0.0163"}, {"groupId": "OG001", "value": "0.2728", "spread": "0.0162"}, {"groupId": "OG002", "value": "0.0574", "spread": "0.0355"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Equivalence of MGR001 and Advair Diskus is established if the ratio of the LS means and 90% confidence interval are wholly contained within the interval 0.80-1.25 (i.e., 80%-125%).", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "A linear analysis of covariance (ANCOVA) model was fitted for the endpoint and least-squares (LS) means were derived for each treatment. To assess equivalence, LS means (one for Test and one for Reference) from the ANCOVA models were used to generate Test/Reference ratios and 90% CIs were calculated by using Fieller's theorem. To demonstrate equivalence, the 90% CIs were each required to be wholly contained within the interval 0.80-1.25 (i.e., 80%-125%).", "paramType": "Ratio (MGR001/Advair Diskus)", "paramValue": "1.069", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.938", "ciUpperLimit": "1.220", "estimateComment": "Bioequivalence was established between active treatments (MGR001 and Advair Diskus) for change from baseline in trough FEV1 endpoint on Day 29"}]}]}, "adverseEventsModule": {"frequencyThreshold": "0.2", "timeFrame": "Adverse events (AEs) were collected from the signing of the ICF but are reported from Day 1 to 30 days after the last dose of double-blind study medication.", "description": "Subjects were routinely queried for AEs using open-ended questions. Spontaneously reported AEs were also recorded. The most frequent AEs occurring in at least 3 subjects across the 3 treatment groups are reported, equating to 0.2% of subjects in the Safety Set.", "eventGroups": [{"id": "EG000", "title": "MGR001", "description": "MGR001 administered two times per day by inhalation throughout the study\n\nMGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device", "deathsNumAffected": 0, "deathsNumAtRisk": 512, "seriousNumAffected": 0, "seriousNumAtRisk": 512, "otherNumAffected": 39, "otherNumAtRisk": 512}, {"id": "EG001", "title": "Advair Diskus", "description": "Advair Diskus administered two times per day by inhalation throughout the study\n\nAdvair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate): Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device", "deathsNumAffected": 0, "deathsNumAtRisk": 512, "seriousNumAffected": 0, "seriousNumAtRisk": 512, "otherNumAffected": 51, "otherNumAtRisk": 512}, {"id": "EG002", "title": "Placebo", "description": "Placebo for Advair Diskus and MGR001 administered two times per day by inhalation throughout the study\n\nPlacebo: Placebo administered via the CRC749 and Diskus devices", "deathsNumAffected": 0, "deathsNumAtRisk": 103, "seriousNumAffected": 0, "seriousNumAtRisk": 103, "otherNumAffected": 10, "otherNumAtRisk": 103}], "otherEvents": [{"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 103}]}, {"term": "Sinusitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Oral candidiasis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Viral upper respiratory tract", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Gastroenteritis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Viral infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 7, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 103}]}, {"term": "Oropharyngeal pain", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 103}]}, {"term": "Dysphonia", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 18.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 512}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 512}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 103}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": true}, "pointOfContact": {"title": "Dik Ng, PhD", "organization": "Mylan Pharma UK Ltd", "email": "dik.ng@mylan.co.uk", "phone": "+44-7467-941703"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000001249", "term": "Asthma"}], "ancestors": [{"id": "D000001982", "term": "Bronchial Diseases"}, {"id": "D000012140", "term": "Respiratory Tract Diseases"}, {"id": "D000008173", "term": "Lung Diseases, Obstructive"}, {"id": "D000008171", "term": "Lung Diseases"}, {"id": "D000012130", "term": "Respiratory Hypersensitivity"}, {"id": "D000006969", "term": "Hypersensitivity, Immediate"}, {"id": "D000006967", "term": "Hypersensitivity"}, {"id": "D000007154", "term": "Immune System Diseases"}], "browseLeaves": [{"id": "M27137", "name": "Respiratory Aspiration", "relevance": "LOW"}, {"id": "M4556", "name": "Asthma", "asFound": "Asthma", "relevance": "HIGH"}, {"id": "M5258", "name": "Bronchial Diseases", "relevance": "LOW"}, {"id": "M14977", "name": "Respiratory Tract Diseases", "relevance": "LOW"}, {"id": "M11168", "name": "Lung Diseases", "relevance": "LOW"}, {"id": "M11170", "name": "Lung Diseases, Obstructive", "relevance": "LOW"}, {"id": "M10018", "name": "Hypersensitivity", "relevance": "LOW"}, {"id": "M14967", "name": "Respiratory Hypersensitivity", "relevance": "LOW"}, {"id": "M10020", "name": "Hypersensitivity, Immediate", "relevance": "LOW"}, {"id": "M10200", "name": "Immune System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC08", "name": "Respiratory Tract (Lung and Bronchial) Diseases"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC20", "name": "Immune System Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068298", "term": "Fluticasone"}, {"id": "C000716389", "term": "Xhance"}, {"id": "D000068299", "term": "Salmeterol Xinafoate"}], "ancestors": [{"id": "D000000893", "term": "Anti-Inflammatory Agents"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000003879", "term": "Dermatologic Agents"}, {"id": "D000018926", "term": "Anti-Allergic Agents"}, {"id": "D000058666", "term": "Adrenergic beta-2 Receptor Agonists"}, {"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M250", "name": "Fluticasone", "asFound": "Pembrolizumab", "relevance": "HIGH"}, {"id": "M353494", "name": "Xhance", "asFound": "Membrane", "relevance": "HIGH"}, {"id": "M251", "name": "Salmeterol Xinafoate", "asFound": "Healthy diet", "relevance": "HIGH"}, {"id": "M249", "name": "Fluticasone-Salmeterol Drug Combination", "relevance": "LOW"}, {"id": "M4217", "name": "Anti-Inflammatory Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M7074", "name": "Dermatologic Agents", "relevance": "LOW"}, {"id": "M20962", "name": "Anti-Allergic Agents", "relevance": "LOW"}, {"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AAll", "name": "Anti-Allergic Agents"}, {"abbrev": "Infl", "name": "Anti-Inflammatory Agents"}, {"abbrev": "Derm", "name": "Dermatologic Agents"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}